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Background: Wheezing during early life is a very common disorder, but the reasons underlying the different
wheezing phenotypes are still unclear. The aims of this study were to analyse the potential correlations between
the risk of developing recurrent wheezing and the presence of specific polymorphisms of some genes regulating
immune system function, and to study the relative importance of the associations of different viruses and genetic
polymorphisms in causing recurrent episodes.
Methods: The study involved 119 otherwise healthy infants admitted to hospital for a first episode of wheezing
(74 of whom subsequently experienced recurrent episodes) and 119 age- and sex-matched subjects without any
history of respiratory problem randomly selected from those attending our outpatient clinic during the study
period. All of the study subjects were followed up for two years, and 47 single nucleotide polymorphisms (SNPs)
in 33 candidate genes were genotyped on whole blood using an ABI PRISM 7900 HT Fast Real-time instrument.
Results: IL8-rs4073AT, VEGFA-rs833058CT, MBL2-rs1800450CT and IKBKB-rs3747811AT were associated with a significantly
increased risk of developing wheezing (p = 0.02, p = 0.03, p = 0.05 and p = 0.0018), whereas CTLA4-rs3087243AG
and NFKBIB-rs3136641TT were associated with a significantly reduced risk (p = 0.05 and p = 0.04). IL8-rs4073AT,
VEGFA-rs2146323AA and NFKBIA-rs2233419AG were associated with a significantly increased risk of developing
recurrent wheezing (p = 0.04, p = 0.04 and p = 0.03), whereas TLR3-rs3775291TC was associated with a significantly
reduced risk (p = 0.03). Interestingly, the study of gene-environment interactions showed that rhinovirus was significantly
associated with recurrent wheezing in the presence of IL4Ra-rs1801275GG and G (odds ratio [OR] 6.03, 95% confidence
interval [CI]: 1.21-30.10, p = 0.03) and MAP3K1-rs702689AA (OR 4.09, 95% CI: 1.14-14.61, p = 0.03).
Conclusions: This study shows a clear relationship between the risk of wheezing and polymorphisms of some genes
involved in the immune response. Although further studies are needed to confirm the results, these findings may
be useful for the early identification of children at the highest risk of developing recurrent episodes and possibly
subsequent asthma.
Keywords: Asthma, Genetic polymorphisms, Lower respiratory tract infection, Recurrent wheezing, Respiratory
viruses, WheezingBackground
Wheezing during early life is a very common disorder:
longitudinal birth cohort studies have estimated that
its cumulative prevalence during pre-school years is
approximately 50% [1]. In most cases, wheezing in
infants and young children is associated with a viral* Correspondence: susanna.esposito@unimi.it
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to respiratory syncytial virus (RSV) or rhinovirus (RV),
and less frequently to other viruses such as human metap-
neumovirus, bocavirus and parainfluenza virus [2].
Some children experience only one episode of wheezing
or a very small number of infrequent recurrences, and are
usually not affected by significant respiratory problems
in later life. However, a substantial number of children
experience wheezing every time they suffer from a respira-
tory viral infection, and up to 50% of these subjectsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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these different wheezing phenotypes are still unclear. A
number of clinical and epidemiological studies have
shown that the severity of individual episodes, the risk
of recurrence, and the risk of developing asthma are
frequently associated with the presence of atopy or
particular clinical or environmental conditions such as
prematurity and exposure to tobacco smoke [4,5]. Micro-
biological studies have shown that not all viruses have the
same potential for causing severe or recurrent cases, and
that RSV [6] and RV [7] are more frequently identified
in the respiratory secretions of subjects with recurrent
wheezing. However, analysis of the data collected in
studies of the possible relationships between viral
LRTIs and wheezing has shown that, even in the
absence of known risk factors, a considerable number
of children experience severe and/or frequently recurring
infections with wheezing, and develop asthma during
adolescence [2].
It has been suggested that alterations in the innate and
adaptive immune responses to viral LRTIs may favour
virus-induced airway dysfunctions that lead to more
severe signs and symptoms, and long-lasting changes in
the anatomic and histological characteristics of the
respiratory tree that predispose to recurrences and the
development of asthma [8], and a number of studies
indicate that these risks seem to be closely associated
with genetic polymorphisms of the genes encoding
factors involved in innate and adaptive immunity [9-11].
However, little is known about which immune response
mechanisms modified by genetic defects play the major
role in conditioning susceptibility to wheezing, or what
can be done to increase host defences in such cases. The
precise identification of the specific genetic variants
involved in immunity that are associated with an increased
risk of LRTIs with recurrent wheezing has foreseeable
applications in pediatrics, preventive medicine and vaccine
development, and it can be expected that analysing
methods that can reduce the negative impact of genetic
defects in innate or adaptive immunity will have consider-
able consequences.
The aims of this study were to analyse the potential
correlations between the risk of developing recurrent
LRTIs with wheezing and the presence of specific poly-
morphisms of some genes that regulates immune system
function, and to study the relative importance of the
associations of different viruses and genetic polymor-
phisms in causing recurrent episodes.
Methods
Study population and recruitment
The study was carried out in the Pediatric Highly Inten-
sive Care Unit of the Fondazione IRCCS Ca’ Granda,
Ospedale Maggiore Policlinico, Milan, Italy, betweenNovember 2010 and September 2013. The protocol was
approved by the Ethics Committee of the Fondazione
IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, and
written informed consent was obtained from the parents
or legal guardian of each patient before enrolment.
The study initially involved 138 otherwise healthy
infants aged ≤12 months admitted to hospital because
of a first episode of RTI with wheezing diagnosed on
the basis of well-established criteria [12]. In particular,
were infants with clinical evidence of respiratory tract
infection with fever, stuffed or runny nose, sneezing and/
or cough accompanied by wheezing (i.e. a continuous
high-pitched sound with musical quality emitting from
the chest during expiration) were enrolled. The exclusion
criteria were premature birth or the presence of a chronic
disease increasing the risk of complications of a respira-
tory infection (i.e. a chronic pulmonary or cardiovascular
system disorder, chronic metabolic disease, neoplasia,
kidney or liver dysfunction, hemoglobinopathy, immuno-
suppression, and or genetic or neurological disorders).
After selection, there was no refusal to participate. Upon
enrolment, the demographic characteristics and medical
history of the infants were systematically recorded using
standardised written questionnaires, and specimens for
the detection of respiratory viruses were taken using flex-
ible pernasal flocked swabs and 1 mL of universal trasport
medium (Kit Cat. No. 360c, Copan Italia, Brescia, Italy).
At enrolment, a 3 mL whole blood sample was also
obtained for genetic studies.
After enrolment, all of the children were followed up
for 24 months in order to monitor the incidence of new
wheezing episodes. To this end, the parents were asked
to bring their children to the centre for a control visit
every month, and every time their children experienced
a febrile episode accompanied by symptoms suggesting
an LRTI, such as cough, tachypnea, grunting, chest in-
drawing, feeding difficulties, airway noise, irritability and
poor sleep. The parents were also asked to complete a
diary recording all of their children’s clinical problems
and the administration of any drug including antipyretics.
To overcome the problem of the possible under-reporting
of wheezing episodes, all of the families were systematic-
ally telephoned weekly to verify the children’s status.
All of the medical examinations (the planned monthly
examinations and those following the development of a
febrile episode) were carried out by trained investiga-
tors (SE and CT) using standardised questionnaires. At
each visit, the details of any medical event occurring
since the previous visit were recorded, and the children
underwent a complete physical examination.
The controls were 119 age- and gender-matched healthy
subjects with a negative history for LRTIs and wheezing,
and no respiratory problems during their first two years of
life, who were randomly selected on the basis of a
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ing the outpatient clinic for clinical control after minor
surgical procedures during the study period. Although
controls were clinically followed since the same age of the
study patients, a 3 mL whole blood sample for genetic
studies from them was obtained when they were aged 24
months in order to be sure that they did not suffer from
wheezing episodes during the first years of life.
Identification of viral infections
Viral RNA or DNA was extracted from the respiratory
secretions by means of a Nuclisens EasyMAG automated
extraction system (Biomeriéux, Craponne, France), and
was then tested using the Luminex x TAG respiratory
virus panel fast assay (Luminex Molecular Diagnostics
Inc., Toronto, Canada) in order to detect influenza A
virus (subtype H1 or H3), influenza B virus, RSV-A and -B,
parainfluenzavirus-1, −2, −3 and −4, adenovirus, human
metapneumovirus, coronaviruses 229E, NL63, OC43 and
HKU1, enterovirus/RV and human bocavirus in accordance
with the manufacturer’s instructions [13,14]. The entero-
virus/RV-positive samples were retested by means of a
real-time polymerase chain reaction (RT-PCR) assay
using the one-step iAg-Path-ID RT-PCR kit (Applied
Biosystems, Foster City, CA), and the primers and
probe sequences reported by Lu et al. [15] in order to
identify the type of RV.
Genetic studies
Candidate genes
Thirty-three candidate genes and 47 single nucleotide
polymorphisms (SNPs) were selected for analysis, including
genes involved in immune regulation, and the pathogenesis
of inflammation and wheezing. The selected genes encode
transcription (CHUK, IKIKB, JUN, NFKB1A, NFKB1B)
and transduction factors (MAP3K1), the regulator of T cell
activity (CTLA4), pattern recognition receptors (IL1RL1,
TLR1, TLR3, TLR4, TLR5, TNFRSF1B), pro-inflammatory
cytokines and related receptors (IL13, IL18, IL18RAP),
anti-inflammatory cytokines (IL10, IL19, IL20), the cytokine
regulating lymphoid cell survival (IL7), chemokines (CCL5,
IL8, CXCL9), the regulator of IgE production (IL4R), collec-
tins (MBL2), the protein responsible for the acute response
to bacterial lipopolysaccharides (LBP), growth factors (NGF,
VEGFA), the protein involved in the structural maintenance
of chromosomes (RAD50), the spermatogenesis-associated
serine-rich 2-like SPATS2L, the thromboxane A2 receptor
(TBXA2R), and the adrenergic beta 2 surface receptor
(ADRB2), and all are located on autosomes. In most cases,
the SNPs were functional variants or tagging SNPs charac-
terised by the International HapMap Project. The studied
SNPs are involved in causing or determining the severity or
outcome of wheezing in experimental animals or humans,
or have previously been found to be associated with anincreased risk of developing asthma or an abnormal
immune response [16-47]. The investigated genes and
SNPs are listed in Table 1.
DNA extraction
DNA was extracted using the Masterpure DNA Purifica-
tion kit (Epicentre, Madison, FL) in accordance with the
manufacturer’s instructions, and a 50 μL final elution
volume after purification. The extracted DNA was quanti-
fied using Picogreen reagent (Life Technologies, Monza,
Italy) and an Infinite M200 PRO fluorimeter (Tecan Italia,
Cernusco Sul Naviglio, Italy). Following the nucleic acid
purification procedures, the samples were stored at −20°C
until use.
Genotyping
Forty-seven SNPs in the 33 genes were genotyped using
the Custom TaqMan® Array Microfluidic Cards genotyping
system on an ABI 7900HT (Applied Biosystems, Foster
City, CA). After PCR amplification, the alleles were
detected by means of end-point analysis using SDS and
TaqMan Genotyper software (Applied Biosystems, Foster
City, CA). The data were entered into a Progeny database
(Progeny Software, LLC, South Bend, IN) for the gener-
ation of datasets for analysis.
Statistical analysis
A sample size of 119 subjects in each of the two groups
achieved 80% power (with alpha = 0.05) to detect an
unadjusted odds ratio (OR) of 2.1, assuming that in the
control group the proportion of children with a given
polymorphic allele for a given gene was 0.30. The test
statistic used was the two-sided Mantel-Haenszel test.
The categorical data were compared between the
groups using contingency table analysis with the χ2 or
Fisher’s exact test, as appropriate. The continuous data
were analysed using a two-sided Student’s t-test after
checking that they were normally distributed (based on
the Shapiro-Wilk statistic), or a two-sided Wilcoxon rank-
sum test otherwise. Genotype frequencies were determined
by means of direct counting. In order to investigate the
Hardy-Weinberg equilibrium (HWE), the expected num-
ber of each genotype was compared with the observed
number, and potential deviations were assessed using
the chi-squared or likelihood ratio test, as appropriate.
Age-adjusted OR and their 95% confidence intervals (CI)
were calculated in order to measure the associations
between selected SNPs and: 1) susceptibility to wheezing
by comparing all of the children with wheezing with
the controls; 2) susceptibility to recurrent wheezing by
comparing the children who experienced more than
one episode of wheezing during with those who did not.
The data were controlled for multiple testing using the
false discovery rate method (with the Benjamini-Hochberg
Table 1 Gene and single nucleotide polymorphisms (SNPs)
Gene dbSNP HGVS description Functional consequence Position (bp) Chr Gene location
ADRB2 Rs1042713 NC_000005.9:g.148206440G > A Mis-sense 148206440 5 Exon
CCL5 Rs2280788 NC_000017.10:g.34207405G > C Upstream variant 2 KB 34207405 17 Intergenic
CHUK Rs3808916 NC_000010.10:g.101947737C > T Downstream variant 101947737 10 Intergenic
CTLA4 Rs3087243 NC_000002.11:g.204738919G > A Downstream variant 204738919 2 Intergenic
CXCL9 Rs2276886 NC_000004.11:g.76928428C > T Intron variant 76928428 4 Intron
JUN Rs11688 NC_000001.10:g.59247993C > T Transition substitution 59247993 1 Exon
IKIKB Rs3747811 NC_000008.10:g.42129505A > T Intron variant 42129505 8 Intron
Rs10958713 NC_000008.10:g.42180716C > T Intron variant 42180716 8 Intron
IL1RL1 Rs1921622 NC_000002.11:g.102966067G > A Intron variant 102966067 2 Intron
IL1R2 Rs740044 NC_000002.11:g.102600169A > C Transversion substitution 102600169 2 Exon
IL4R Rs1805010 NC_000016.9:g.27356203A > G Mis-sense 27356203 16 Exon
Rs1805015 NC_000016.9:g.27374180 T > C Mis-sense 27374180 16 Exon
Rs1801275 NC_000016.9:g.27374400A > G Mis-sense 27374400 16 Exon
IL7 Rs2583762 NC_000008.10:g.79697483A > T Intron variant 79697483 8 Intron
IL8 Rs4073 NC_000004.11:g.74606024A > T Upstream variant 2 KB 74606024 4 Intergenic
IL10 Rs1800872 NC_000001.10:g.206946407 T > G Upstream variant 2 KB 206946407 1 Intergenic
Rs1800896 NC_000001.10:g.206946897 T > C Upstream variant 2 KB 206946897 1 Intergenic
IL13 Rs20541 NC_000005.9:g.131995964A > G Mis-sense 131995964 5 Exon
Rs1800925 NC_000005.9:g.131992809C > T Upstream variant 2 KB 131992809 5 Intergenic
IL18 Rs187238 NC_000011.9:g.112034988C > G Upstream variant 2 KB 112034988 11 Intragenic
IL18RAP Rs917998 NC_000002.11:g.103068156C > T Intron variant 103068156 2 Intron
Il19 Rs2243188 NC_000001.10:g.207014472A > C Intron variant 207014472 1 Intron
Rs2243191 NC_000001.10:g.207015957 T > C Mis-sense 207015957 1 Exon
IL20 Rs2981573 NC_000001.10:g.207040577G > A Intron variant 207040577 1 Intron
LBP Rs12624843 NC_000020.10:g.36989096G > A Intron variant 36989096 20 Intron
MBL2 Rs1800450 NC_000010.10:g.54531235C > T Mis-sense 54531235 10 Exon
Rs1800451 NC_000010.10:g.54531226C > T Mis-sense 54531226 10 Exon
Rs5030737 NC_000010.10:g.54531242G > A Mis-sense 54531242 10 Exon
MAP3K1 Rs702680 NC_000005.9:g.56220382 T > C Intron variant 56220382 5 Intron
Rs889312 NC_000005.9:g.56031884C > A Upstream variant 56031884 5 Intergenic
NFKB1A Rs2233419 NC_000014.8:g.35871960G > A Intron variant 35871960 14 Intron
Rs3138052 NC_000014.8:g.35875021 T > C Upstream variant 2 KB 35875021 14 Intergenic
NFKB1B Rs3136641 NC_000019.9:g.39396649C > T Intron variant 39396649 19 Intron
NGF Rs11102930 NC_000001.10:g.115881055G > A Upstream variant 2 KB 115881055 1 Intergenic
RAD50 Rs2706347 NC_000005.9:g.131905117G > T Intron variant 131905117 5 Intron
SPATS2L Rs295137 NC_000002.11:g.201150040C > T Upstream variant 201150040 2 Intergenic
TBXA2R Rs4523 NC_000019.9:g.3595794A > G Synonymous codon 3595794 19 Exon
TLR1 Rs4543123 NC_000004.11:g.38792524A > G Downstream variant 38792524 4 Intergenic
TLR3 Rs1519309 NC_000004.11:g.187015089C > T Downstream variant 187015089 4 Intergenic
Rs3775291 NC_000004.11:g.187004074C > T Mis-sense 187004074 4 Exon
TLR4 Rs2737190 NC_000009.11:g.120464181G > A Upstream variant 120464181 9 Intergenic
Rs4986790 NC_000009.11:g.120475302A > G Mis-sense 120475302 9 Exon
Rs4986791 NC_000009.11:g.120475602C > T Mis-sense 120475602 9 Exon
TLR5 Rs2241096 NC_000001.10:g.223310048G > A Intron variant 223310048 5 Intron
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Table 1 Gene and single nucleotide polymorphisms (SNPs) (Continued)
TNFRSF1B Rs1061622 NC_000001.10:g.12252955 T > G Mis-sense 12252955 1 Exon
VEGFA Rs833058 NC_000006.11:g.43731854C > T Upstream variant 43731854 6 Intergenic
Rs2146323 NC_000006.11:g.43745095C > A Intron variant 43745095 6 Intron
Chr chromosome, HGVS Human Genome Variation Society - Genome Build 37.1 (www.ncbi.nlm.nih.gov); the position reflects the distance from short-arm telomere.
Bp base pairs.
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SAS software, version 9.2 (Cary, NC, USA).Results
Nineteen children included in the group of patients were
lost during the study period because parents refused the
return every month to the study center and did not
adequately collected information regarding respiratory
infections of their children. Consequently, 119 patients
were considered and compared to controls. Table 2 sum-
marises the demographic and clinical characteristics of
the study population. Gender and age distribution was
similar between the children with wheezing and controls,
and between the children with non-recurrent and recur-
rent wheezing. Most of the subjects were Caucasian, and
all of them had been born at term. The duration of breast-
feeding, use of pacifier and having at least one older
sibling were similar between the groups, but exposure to
cigarette smoke, high IgE levels and a family history of
atopy were significantly more frequent among the chil-
dren with wheezing than the controls (p = 0.002, p < 0.001
and p < 0.001), and a family history of atopy was signifi-
cantly more frequent among the children with recurrent
than those with non-recurrent wheezing (p = 0.001).Table 2 Demographic and clinical characteristics of the study
Characteristic Control group
(n = 119)
Children with
wheezing (n = 119)
P-va
Females, n (%) 43 (36.1) 43 (36.1) 1.0
Median age (range), months 6 (0.3-12) 6 (0.3-12) 1.0
Caucasians, n (%) 113 (95.0) 113 (95.0) 1.0
Median gestational age
(range), weeks
38.3 (37-41) 38.1 (37-41) 0.9
Subjects breastfed ≥3 months,
n (%)
82 (68.9) 73 (61.3) 0.2
Subjects regularly using
pacifier, n (%)
30 (25.2) 31 (26.1) 1.0
Subjects with at least one
older sibling, n (%)
28 (23.5) 33 (27.7) 0.5
Subjects exposed to
cigarette smoke, n (%)
55 (46.2) 79 (66.4) 0.0
Subjects with high IgE
levels, n (%)
11 (9.2) 76 (63.9) <0.0
Subjects with a family
history of atopy, n (%)
24 (20.2) 85 (71.4) <0.0The selected SNP allele frequencies were similar in the
children with any type of wheezing and in the controls,
and similar in the children with non-recurrent or recurrent
wheezing. All of the examined SNPs were present in the
study population.
Table 3 shows the SNP genotype frequencies that were
significantly different between the children with wheezing
and that controls, and Table 4 those that were significantly
different between the children with non-recurrent wheez-
ing and those with recurrent wheezing. IL8-rs4073AT,
VEGFA-rs833058CT, MBL2-rs1800450CT and IKBKB-
rs3747811AT were associated with a significantly increased
risk of developing wheezing (p = 0.02, p = 0.03, p = 0.05 and
p = 0.0018), whereas CTLA4-rs3087243AG and NFKBIB-
rs3136641TT were associated with a significantly reduced
risk (p = 0.05 and p = 0.04). IL8-rs4073AT, VEGFA-rs2146
323AA and NFKBIA-rs2233419AG were associated with
a significantly increased risk of developing recurrent
wheezing (p = 0.04, p = 0.04 and p = 0.03), whereas TLR3-
rs3775291TC was associated with a significantly reduced
risk (p = 0.03). No other differences in genotype frequen-
cies were found.
Table 5 shows the distribution of viral infections in the
children with non-recurrent or recurrent wheezing. RSV
was the most frequently detected pathogen in the majoritypopulation at the time of onset of first wheezing episode
lue Children with non-recurrent
wheezing (n = 45)
Children with recurrent
wheezing (n = 74)
P-value
0 16 (35.6) 27 (36.5) 0.92
0 6 (0.3-12) 6 (0.3-12) 1.00
0 42 (93.3) 71 (95.9) 0.67
7 38.2 (37-41) 37.6 (37-40) 0.94
7 29 (64.4) 44 (59.5) 0.72
0 10 (22.2) 21 (28.4) 0.59
5 12 (26.7) 21 (28.4) 0.99
02 26 (57.8) 53 (71.6) 0.17
01 24 (53.3) 52 (70.3) 0.09
01 24 (53.3) 61 (82.4) 0.001
Table 3 Genotype frequencies of selected SNPs in controls and children with bronchospasma
Observed Expected
Gene and
polymorphic alleles
Control group
(n = 119)
Children with
wheezing (n = 119)
Control group
(n = 119)
Children with
wheezing (n = 119)
HWE, χ2
controls
HWE, χ2
wheezing
N % N % N % N % p-value p-value ORb 95% CI p-valuec
IL8-rs4073
A 28 23.7 21 17.8 22.5 19.0 20.8 17.6 1.00 (Reference) -
A/T 47 39.8 57 48.3 58.0 49.2 57.5 48.7 2.50 (1.15-5.44) 0.02
T 43 36.4 40 33.9 37.5 31.8 39.8 33.7 0.04 0.93 1.57 (0.71-3.45) 0.27
VEGFA-rs833058
C 32 27.1 22 18.5 32.6 27.6 28.3 23.8 1.00 (Reference) -
C/T 60 50.9 72 60.5 58.8 49.9 59.5 50.0 2.22 (1.09-4.55) 0.03
T 26 22.0 25 21.0 26.6 22.5 31.3 26.3 0.83 0.02 1.96 (0.83-4.65) 0.13
MBL2-rs1800450
C 87 73.7 76 63.9 87.3 74.0 77.4 65.1 1.00 (Reference) -
C/T 29 24.6 40 33.6 28.4 24.1 37.1 31.2 1.90 (1.01-3.58) 0.05
T 2 1.7 3 2.5 2.3 2.0 4.4 3.7 0.81 0.40 1.03 (0.15-7.23) 0.97
IKBKB-rs3747811
A 36 31.3 20 17.1 28.3 24.6 24.5 20.9 1.00 (Reference) -
A/T 42 36.5 67 57.3 57.5 50.0 58.1 49.6 3.26 (1.55-6.85) 0.0018
T 37 32.2 30 25.6 29.3 25.4 34.5 29.5 0.004 0.10 2.01 (0.89-4.53) 0.09
CTLA4-rs3087243
A 25 21.2 35 29.7 32.1 27.2 35.8 30.3 1.00 (Reference) -
A/G 73 61.9 60 50.9 58.9 49.9 58.4 49.5 0.50 (0.25-0.99) 0.05
G 20 17.0 23 19.5 27.1 22.9 23.8 20.2 0.009 0.76 0.65 (0.27-1.56) 0.34
NFKBIB-rs3136641
C 64 54.2 72 61.0 59.8 50.7 71.0 60.1 1.00 (Reference) -
C/T 40 33.9 39 33.1 48.4 41.0 41.1 34.8 0.90 (0.49-1.66) 0.73
T 14 11.9 7 5.9 9.8 8.3 6.0 5.0 0.06 0.58 0.33 (0.11-0.94) 0.04
aThe sums may not add up to the total because of a few missing values; bOdds ratios adjusted for age (< / ≥ 2 years). cp-values from univariate analyses, not
adjusted for multiple testing. None of the p-values was significant after correction for multiple testing.
HWE Hardy-Weinberg equilibrium, NE Not estimable.
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RSV was significantly higher in patients with non-recurrent
wheezing than in those with recurrent episodes (p = 0.02).
Interestingly, the study of gene-environment interactions
showed that RV was significantly associated with recurrent
wheezing in the presence of IL4Ra-rs1801275GG and G
(OR 6.03, 95% CI: 1.21-30.10, p = 0.03) and MAP3K1-
rs702689AA (OR 4.09, 95% CI: 1.14-14.61, p = 0.03). No
significant difference was observed in the distribution
of genetic polymorphisms among the children with RSV
or other viral infections and non-recurrent or recurrent
wheezing.
Discussion
This study shows that genetic polymorphisms seem to
play a substantial role in conditioning the risk of wheezing
in young children with viral LRTI. Susceptibility to thedevelopment of wheezing seems to be greater in children
with SNPs of the IL8 (rs4073AT), VEGFA (rs833058CT),
MBL2 (rs1800450CT) and IKBKB genes (rs3747811AT).
The association with IL8, VEGFA and MBL2 genes is not
surprising because the factors encoded by them play an
important role in immunity and have been previously
associated with bronchial obstruction [8-11].
IL8 is one of the most important chemotactic factors
for leukocyte recruitment and activation in the lung, and
has to be controlled to prevent excessive tissue injury
and possibly damaging systemic effects [1]. The SNP of
IL8 evaluated in this study has previously been found to
be significantly associated with severe RSV bronchiolitis
and recurrent wheezing episodes [22], and it has also
been found that a high concentration of IL-8 in cord
blood is significantly associated with persistent wheezing
at the age of one year [23]. Its importance in conditioning
Table 4 Genotype frequencies of selected SNPS with significant differences in children with recurrent or non-recurrent
wheezinga
Observed Expected
Gene and
polymorphic alleles
Non-recurrent
(n = 74)
Recurrent
wheezing
(n = 45)
Non-recurrent
(n = 74)
Recurrent
wheezing
(n = 45)
HWE, χ2
non-recurrent
HWE, χ2
recurrent
N % N % N % N % p-value p-value ORb 95% CI p-valuec
IL8-rs4073
A 17 23.3 4 8.9 12.3 16.9 8.5 18.8 1.00 (Reference) -
A/T 26 35.6 31 68.9 35.3 48.4 22.1 49.1 3.60 (1.03-12.57) 0.04
T 30 41.1 10 22.2 25.3 34.7 14.5 32.1 0.02 0.007 1.18 (0.31-4.51) 0.81
VEGFA-rs2146323
A 4 5.4 8 17.8 6.8 9.2 6.8 15.1 4.32 (1.06-17.64) 0.04
A/C 37 50.0 19 42.2 31.3 42.3 21.4 47.5 1.08 (0.46-2.54) 0.85
C 33 44.6 18 40.0 35.8 48.4 16.8 37.3 0.12 0.45 1.00 (Reference) -
TLR3-rs3775291
T 10 13.7 4 8.9 8.9 12.2 2.5 5.4 0.75 (0.20-2.75) 0.66
T/C 31 42.5 13 28.9 33.2 45.5 16.1 35.8 0.36 (0.14-0.90) 0.03
C 32 43.8 28 62.2 30.9 42.3 26.5 58.8 0.57 0.20 1.00 (Reference) -
NFKBIA-rs2233419
A 5 6.8 2 4.4 1.9 2.6 2.2 4.9 0.82 (0.13-5.05) 0.83
A/G 14 18.9 16 35.6 20.1 27.2 15.6 34.6 2.79 (1.12-6.99) 0.03
G 55 74.3 27 60.0 51.9 70.2 27.2 60.5 0.009 0.85 1.00 (Reference) -
aThe sums may not add up to the total because of a few missing values; bOdds ratios adjusted for age (< / ≥ 2 years). cp-values from univariate analyses, not
adjusted for multiple testing. None of the p-values was significant after correction for multiple testing. HWE Hardy-Weinberg equilibrium.
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ing that it was the only genetic polymorphism associated
with the risk of wheezing and susceptibility to recurrent
episodes.
VEGFA is a major regulator of angiogenesis and enhan-
cer of vascular permeability [24], and seems to induce
airway inflammation and airway remodelling in patients
with asthma [25]. High VEGFA levels have been found
in subjects with chronic pulmonary diseases [26] and
certain kinds of pneumonia [27], and have been found
to be significantly higher in the serum of children with
Mycoplasma pneumoniae infection and wheezing than
in healthy controls [28].
MBL2 is a protein belonging to the collectin family
that is important in the innate immune system [29]. It
recognises mannose and N-acetylglucosamine on many
micro-organisms, and is capable of activating the classical
complement pathway. Deficiencies in this gene have been
associated with susceptibility to autoimmune and infectious
diseases [29], and a well-defined but weak association has
been found between some SNPs of MBL2 and asthma and
atopy in children [29].
There is no previous report of an association between
the IKBKB gene and increased susceptibility to wheezing.
This gene encodes IkB kinase 2 (IKK2, also known as
IKKβ), a component of the IKK–nuclear factor κB(NF-κB) pathway [30]. A number of primary immunodefi-
ciencies leasing to an increased risk of infection and
autoimmunity are caused by an impaired IKK–IκB axis
[30] and, as IKKs are required for the IL17-dependent
signalling associated with neutrophilia and pulmonary
inflammation [31], and IL17 levels have been found to be
higher in patients with asthma [32], it is possible that SNPs
of IKBKB could lead to an increased risk of wheezing.
A reduced risk of developing wheezing was found in
the children with CTLA4 and NFKBIB SNPs, and TLR3
SNP was associated with a reduced risk of developing
recurrent wheezing. The data concerning NFKBIB, a
factor involved in innate immunity, conflict with those
collected by Daley et al. [10] and Sharma et al. [11],
who studied a large number of SNPs and found that
children with a genetic abnormality in NFKBIB and viral
respiratory infection in early life were at increased risk of
developing asthma. The data concerning CTLA4 are in
line with the findings of some authors [34], but not others
[35]. This factor plays an essential role in the function of
the regulatory T cells that control Th1 and Th2 immune
responses [33], and Borrego et al. have reported that, in
comparison with healthy children, CTLA4 expression is
diminished in wheezy subjects and those at high risk of
asthma, thus suggesting that impaired CTLA4 expression
may play a role in reducing bronchial obstruction [34].
Table 5 Frequency distribution of viral infections in
children with recurrent or non-recurrent wheezing
Viral infection Non-recurrent
wheezing (n = 74)
Recurrent
wheezing (n = 45)
N % N % p-value
RSV
No 21 28.4 22 48.9
Yes 53 71.6 23 51.1 0.02
RV (any type)
No 59 79.7 33 73.3
Yes 15 20.3 12 26.7 0.42
Enterovirus
No 70 94.6 37 82.2
Yes 4 5.4 8 17.8 0.055
Coronavirus
(any type)
No 71 96.0 43 95.6
Yes 3 4.0 2 4.4 1.00
Metapneumovirus
No 68 91.9 43 95.6
Yes 6 8.1 2 4.4 0.71
Bocavirus
No 72 97.3 43 95.6
Yes 2 2.7 2 4.4 0.63
Influenza (any type)
No 72 97.3 44 97.8
Yes 2 2.7 1 2.2 1.00
Parainfluenza
(any type)
No 72 97.3 45 100.0
Yes 2 2.7 0 0.0 0.53
Any viral infection
No 7 9.5 8 17.8
Yes 67 90.5 37 82.2 0.18
p-values from chi-squared or Fisher’s exact test, as appropriate. RSV respiratory
syncytial virus, RV rhinovirus. The frequency of RSV was significantly higher in
patients with non-recurrent wheezing than in those with recurrent episodes
(p = 0.02).
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was significantly more frequent in children with wheezing
than in healthy controls [35].
TLR3 recognises dsRNA derived from respiratory viruses
and activates nuclear factor-κB, which increases interferon-
γ signalling in other cells and transforms airway inflamma-
tion into asthma [36]. Th2 cytokines participate in this
process by modulating the response of airway epithelium
and dendritic cells to dsRNA11 and, in the context of RV
infection, the binding of viral dsRNA to TLR3 initiates
pro-inflammatory signalling pathways that lead to airwayinflammation and hyper-responsiveness [37]. Contrary to
our own findings, Nuolivirta et al. found that TLR3-
rs3752291TC was associated with an increased risk of
bronchiolitis and that TLR3-rs3752291CC was significantly
more frequent in patients with recurrent wheezing [38].
Moreover, Daley et al. documented a positive association
between TLR3 SNPs and atopic asthma [10]. These dis-
crepancies may be due to differences in the ethnicity and
general characteristics of the study populations, such as
differences in wheezing phenotypes, because it has been
found that recurrent wheezing during the first year after
viral LRTI and recurrent wheezing at the age of six years
are distinct entities with their own specific immunological
and genetic characteristics [39]. It also possible that the
results were influenced by gene-gene interactions and/or
differences in HWE.
Our findings regarding the associations between SNPs
and gene-environment interactions are also partially
different from those of previous studies. As expected,
RSV was the most frequently detected pathogen in our
study, and its frequency was significantly higher in chil-
dren with non-recurrent wheezing than in those with
recurrent episodes. This may be explained by the fact that
the vast majority of our patients were affected by RSV
infection, but there was no difference in the distribution
of genetic polymorphisms between the children with
recurrent or non-recurrent episodes due to RSV infection.
On the other hand, RV infection was significantly asso-
ciated with recurrent wheezing in the presence of SNPs in
the IL4Ra and MAP3K1 genes. The IL4Ra gene encodes
the alpha chain of the interleukin-4 receptor, a type I
transmembrane protein that can bind IL4 and IL13 and
thus regulate IgE antibody production in B cells [40],
and the encoded protein can also bind IL4 in T cells to
promote differentiation of Th2 cells. Allelic variations
in this gene have been associated with atopy and allergic
clinical manifestations [40]. Furthermore, RV infections
are a major cause of asthma exacerbations [41,42], and
RVs have also been repeatedly detected in patients with
stable asthma [43]. A number of studies have shown
abnormalities in innate immune responses to viruses in
patients with asthma, particularly deficiencies in the
production of IFN I and III [44-46]. The finding that a SNP
in the IL4Ra gene is associated with recurrent wheezing
episodes during RV LRTI further contributes to explaining
the complications that could follow RV infection.
Similar conclusions can be drawn in relation to the
association between the SNP in the MAP3K1 gene and
wheezing recurrences in children with RV infection. Our
data extend the findings of Szczepankiewicz et al., who
observed an association between asthma and MAP3K1
gene polymorphisms rs702689 and rs889312, and suggested
that genetic variants of the MAP3K1 gene involved in
regulating neurogenic inflammation may contribute to
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activation of the MAPK signalling pathway [47].
Our study has some limitations. First of all, the number
of enrolled subjects was relatively small and further
studies of larger pediatric populations would increase
the probability that the statistical associations found by
us represent true biological differences and reduce the
risk of false positive results. Secondly, although consid-
erable, the number of studied genes and SNPs was
probably less than the number of genes and genetic var-
iations actually involved in regulating the mechanisms
that play a role in conditioning susceptibility to infection
and the development of wheezing. Finally, we did not
evaluate the effect of common environmental exposure
on the associations between the genes of the immune
pathway and wheezing but, as it has been suggested
that environmental exposure may modify the effect of
such genetic variants on disease susceptibility, an analysis
of gene-environmental interactions is necessary before
drawing any definite conclusions.
Conclusions
Our findings show a clear relationship between the risk
of wheezing and polymorphisms of some of the genes
involved in the immune response. Despite not conclusive,
they indicate that genetics play an important role in
conditioning wheezing development. However, given
the conflicting literature, further large studies are needed in
order to establish which are the real associations between
wheezing development and genetic variations.
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